Serostim

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2002
012319962002

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
  • AIDS patient care and STDs
  • 2002
 
Is this relevant?
1999
1999
  • AIDS alert
  • 1999
AIDS wasting is characterized by a loss of lean body mass, including muscle and organ tissue, coupled with increased fat… (More)
Is this relevant?
1999
1999
  • The Body positive
  • 1999
The Health Care Finance Administration (HCFA) has reversed a previous statement concerning Medicaid reimbursement for Serostim… (More)
Is this relevant?
1999
1999
  • AIDS policy & law
  • 1999
The U.S. Health Care Financing Administration (HCFA) reversed an earlier decision and ruled that Texas cannot deny Medicaid… (More)
Is this relevant?
1999
1999
  • AIDS alert
  • 1999
The Texas Health Care Financing Administration (HCFA) had denied Medicaid coverage of Serostim as a cosmetic treatment, but… (More)
Is this relevant?
1998
1998
Injections of serostim have been credited with successful treatment of body fat redistribution in five patients. All of the… (More)
Is this relevant?
1998
1998
AIDS Wasting Syndrome (AWS), a devastating consequence of HIV disease, is defined as involuntary loss of body mass and a… (More)
Is this relevant?
1998
1998
  • Treatment review
  • 1998
Anti-HIV drug therapy can sometimes cause unusual fat distribution problems on the neck or stomach, referred to as truncal… (More)
Is this relevant?
1996
1996
The Third Conference on Retroviruses and Opportunistic Infections discussed, in depth, a number of promising drug therapies on… (More)
Is this relevant?
1996
1996
The Food and Drug Administration's (FDA's) Endocrinologic and Metabolic Drugs Advisory Committee voted not to approve Serostim… (More)
Is this relevant?